MDM2 and neoplasm: To further strengthen these recent findings, TRIM8 was shown to exert its anticancer activity through a joint action that provides, on one hand, the activation of the p53 tumour suppressor role and, on the other, the degradation of MDM2, the main negative regulator of p53 stability [21].